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ABSTRACT 
 
Joshua D. Brattlie: Progress Towards the Design and Synthesis of Novel Anti-tumor  
Neo-tanshinlactone Analogues 
(Under the direction of Kenan Distinguished Professor Kuo-Hsiung Lee) 
 
 The goals of this research are to design and synthesize novel neo-tanshinlactone 
analogues utilizing bioisosterism and molecular modification, and to evaluate their bioactivity as 
anti-breast cancer agents. 
             It has been shown that neo-tanshinlactone (1) and several of its analogues retain potent 
and selective in vitro anti- breast cancer activity. Previous research on neo-tanshinlactone 
focused on designing a more efficient synthetic route to synthesize 4-ethyl neo-tanshinlactone 
(2). This improved route was utilized to design and synthesize new compounds to elucidate 
structure-activity relationships (SAR) of 1. Previously designed novel analogues of 1 also 
revolved around the systematic breakdown of its individual rings. 
 In this continuing study, we designed three target scaffolds (A, B, and C), and three 
target compounds (13, 14, and 15), based on 1 and 2 to study the effects of bioisosterism and 
ring size on bioactivity. Each scaffold systematically replaces a specific, and different, oxygen 
atom with a nitrogen atom. We have successfully synthesized two (13 and 14) target compounds, 
and progress has been made towards the synthesis of the third (15). Compound 13, in which the 
naphthalene ring system of neo-tanshinlactone has been replaced by an indole ring system, has 
been tested for cytotoxicity against seven cancer cell lines and has exhibited a decrease in 
potency and selectivity in comparison to 1 and 2. 
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CHAPTER 1 
 
BREAST CANCER: OVERVIEW, TREATMENTS, AND  
CURRENT THERAPEUTIC AGENTS 
 
1.1 Introduction 
Breast cancer is a form of cancer that develops in the cells of the breast.
1
 Among women 
in the United States, breast cancer is the leading form of cancer and, after lung cancer, is the 
second leading cause of cancer death in women.
1
 Breast cancer is a worldwide problem; the 
World Health Organization estimated that in 2011, 508,000 women died worldwide due to breast 
cancer.
2
 It is also estimated that more than 230,000 new cases of invasive breast cancer, over 
60,000 new cases of carcinoma in situ of the breast, and 40,000 deaths will occur from breast 
cancer in 2014.
1 
While breast cancer is more prevalent in women, men are still susceptible. The 
National Cancer Institute estimates that in 2014, over 2,300 new cases of male breast cancer will 
occur causing an estimate 430 deaths.
3 
1.2 Risk Factors 
Risk factors are described as being something that affects your chances of getting a 
disease. Some risk factors are determined by lifestyle such as the use of tobacco or alcohol, while 
other risk factors cannot be changed. Several risk factors have been shown to be associated with 
the prevalence of breast cancer.
1,4 
Some risk factors include: 
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Gender 
With less than 1% of breast cancer cases being attributed to males, being of the female 
gender is a significant risk factor.
1,5 
Age 
As women increase in age, their chances of acquiring breast cancer increase. The age at 
which women start menstruating and start menopause also affect the risk of breast cancer. 
Women who start menstruating earlier and start menopause later in life have shown an increased 
risk of developing breast cancer.
1,4,6 
 Race 
 Caucasian women tend to be at a higher risk of acquiring breast cancer than African-
American women, although African-American women have a higher risk of death from breast 
cancer.
1 
 Family history and genetic factors 
 A family history of breast cancer is a relevant risk factor for acquiring breast cancer. 
Around 5-10% of all breast cancer cases and between 25-40% of cases in which the patient is 
under the age of 35 have been associated with hereditary factors. Mutations in BRCA1 and 
BRCA2, which are known as breast cancer type 1 and 2 susceptible genes, respectively, have 
been found in 30-40% of familial breast cancer cases. While there is an increased risk with these 
mutations, their presence does not account for all familial breast cancer cases, nor does it mean 
that someone with a mutation in one, or both, of these genes will definitely acquire breast 
cancer.
4,7  
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 Previous occurrence of breast cancer 
 Women who have had previous occurrences of breast cancer or other breast diseases, 
such as atypical epithelial hyperplasia, have an increased risk of acquiring the cancer in the other 
breast or another area within the same breast.
1,4,6 
 Hormone therapy 
 The use of combined hormone therapy, in which postmenopausal women take estrogen 
and progesterone, has been associated with an increased risk of breast cancer. Discontinuation of 
the therapy seems to lower the risk to levels seen before the hormone therapy. While, an 
increased risk in breast cancer has been associated with the use of these hormones, the risk is not 
as great in comparison to women in which menopause was delayed for the same amount of 
time.
1,4,6 
 Lifestyle choices 
 Certain lifestyle choices have also been associated with an increased risk in breast cancer. 
Some of these include: consuming alcohol and tobacco products, not bearing children, not 
breastfeeding, and allowing oneself to become obese or overweight.
1,4,6 
1.3 Treatments and Currently Used Agents 
Because several treatment methods are available to patients to combat breast cancer, 
treatment should be discussed thoroughly with a physician. The choice of treatment will most 
likely be affected by a number of factors including the stage of the disease, patient and physician 
preferences, and characteristics of the patient.
1,8 
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Surgery 
In the case of breast cancer, surgery focuses on removing as much of the cancerous tissue 
as possible. One form of breast cancer surgery is breast-conserving surgery (BCS), also known 
as lumpectomy. BCS is usually done in situations where the cancer is localized to a small area of 
the breast. The surgery is also used as a diagnostic tool to determine whether the cancer has 
spread to the axillary lymph nodes. Radiation therapy is commonly used in combination with 
BCS. Another form of surgery is mastectomy, which removes the entire breast. Mastectomies are 
often done when the cancer is not localized to a small area of the breast or as a prophylactic 
treatment to ensure that the cancer does not metastasize. A radical mastectomy can also be 
performed in which the axillary lymph nodes are removed along with the breast tissue in cases 
where the cancer has spread to the lymph nodes.
1,6,9 
Radiation therapy 
Radiation therapy is generally used in combination with surgery or chemotherapy. In 
combination with surgery, radiation therapy can be used before, in attempt to shrink the size of 
the tumor to allow for a better outcome for surgery, or after, to ensure than any remaining cancer 
cells are eradicated from the breast tissue or surrounding area. Radiation therapy consists of 
treating the affected area with high-energy rays or particles to kill cancer cells.
1,6 
Chemotherapy 
Chemotherapy consists of using drugs that kill breast cancer cells. These drugs tend to 
target highly proliferating cells, so side effects are common as the drugs can target highly 
proliferating normal cells as well as the highly proliferating cancer cells. Chemotherapy is 
usually done as a combination therapy, either pre-surgery in attempt to shrink the size of the 
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tumor or post-surgery in an attempt to rid the body of any remaining cancer cells, and also in 
combination with hormone therapy. The use of multiple chemotherapy drugs in a combination 
therapy can also be highly effective in breast cancer treatment.
1
  Common chemotherapeutic 
agents include: 1) doxorubicin (Fig. 1-1, 1) and epirubicin (Fig 1-1, 2), topoisomerase II 
inhibitors which act by intercalating DNA, and halting replication
10
; 2) paclitaxel (Fig 1-1, 3) 
and docetaxel (Fig 1-1, 4), microtubule inhibitors which disrupt the normal cell division
11
; 3) 5-
fluorouracil (Fig 1-1, 5), a thymidylate synthase inhibitor which prevents the production of 
thymidine necessary for DNA replication
12
; 4) cyclophosphamide (Fig 1-1, 6), a DNA alkylating 
agent which causes inter-strand and intra-strand DNA linkages leading to apoptosis.
12 
Hormone therapy 
Hormone therapy is useful when the cancer cells are positive for estrogen receptors or 
progesterone receptors. Estrogen is able to promote the growth of breast cancer cells via these 
hormone receptors and is the major hormone involved in the development of breast cancer. The 
goal of hormone therapy is to block the actions of estrogen at these receptors and prevent 
estrogen-mediated cancer growth. Tamoxifen (Fig 1-1, 7) has been widely used for hormone 
therapy of breast cancer. Tamoxifen is thought to produce its antitumor activity by competitively 
inhibiting estrogen from acting on hormone receptors. Anastrazole (Fig 1-1, 8) represents 
another class of hormone therapy known as aromatase inhibitors. Anastrazole acts to reduce 
estrogen levels by blocking the actions of aromatase, the enzyme responsible for the generation 
of estrogens in postmenopausal women.
1,13,14,15  
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Figure 1-1. Common chemotherapeutic and hormone therapy agents 
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Targeted therapy 
The identification of the molecular targets EGFR(epidermal growth factor receptor) and 
the related HER-2 (human epidermal growth factor receptor 2) associated with breast cancer has 
allowed for the development of more targeted therapies. HER2 is overexpressed in around 30% 
of early-stage and invasive breast cancer cases.
14,16,17 
A significant correlation has been found 
between the overexpression of HER-2 and the reduced survival rates and increased recurrence 
rates in breast cancer patients.
14,16,17 
Researchers have taken advantage of this discovery to 
develop agents that target HER2. Common targeted therapy agents include: 1) trastuzumab 
(Herceptin), an anti-HER2 monoclonal antibody, which uses a humanized mouse monoclonal 
antibody that targets HER2 on the surface of tumor cells causing internalization and subsequent 
cell cycle inhibition; 2) pertuzumab, another humanized monoclonal antibody which is often 
used in combination with trastuzumab as an HER2 dimerization inhibitor, preventing the 
dimerization of HER2 with other HER receptors; 3) ado-trastuzumab emtansine (Fig 1-2, 9), an 
anti-HER2 antibody drug conjugate in which the antibody portion of the drug targets HER2, and 
once binding occurs the conjugate is internalized and subsequent degradation leads to release of 
the chemotherapeutic drug inside the tumor cell; and 4) lapatinib (Fig 1-2, 10), a dual 
EGFR/HER2 inhibitor, which acts via inhibition of the intracellular kinase domains.
14,16,17
 Figure 
1-3 displays the various actions of targeted therapy agents on EGFR and HER receptors. While 
targeted therapy has been proven to be an effective strategy to treat breast cancer, some 
limitations are still present. Trastuzumab, for example, is effective when the patient is tested 
positive for HER2 receptor overexpression. Since HER2-overexpression is only present in a third 
of breast cancer cases there remains a large population of patients who are unable to benefit from 
this therapy. Also, resistance remains a limitation to targeted therapy. Overexpression of EGFR 
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can negate the effects of trastuzumab on HER2-overexpressing patients as well as shedding of 
the HER2 surface receptor protein.
18
 
Figure 1-2. Common targeted therapy agents 
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Figure 1-3. Therapies targeting EGFR and HER pathways
19 
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CHAPTER 2 
DESIGN AND PROGRESS TOWARD THE SYNTHESIS OF NOVEL NEO-
TANSHINLACTONE ANALOGUES 
 
2.1  Introduction 
 Natural products have been used extensively throughout history as remedies for various 
ailments. In the past, these remedies would have included crude forms of the drug such as teas, 
tinctures or powders. Modern technology has now allowed us to isolate the bioactive constituents 
from natural sources to use as drugs, or drug leads.
1,2 
Natural products offer immense structural 
variety and chemical diversity that are unique and would not likely be discovered by the 
traditional medicinal chemistry approaches.
3,4 
Early efforts in drug discovery from natural 
products led to drugs such as digoxin, morphine, codeine, aspirin, penicillin, and quinine.
2,5
 The 
use of natural products has had a huge impact on modern drug discovery. Between 1984 and 
2004, around 50% of drugs introduced to the market were in some way derived from natural 
products. This percentage increased to 78 in the case of antibacterial agents.
1 
Accordingly, it is 
no surprise that over 60% of all currently used anticancer agents are derived from natural 
products.
6 
For these reasons, our group has maintained interest in the discovery of novel 
anticancer agents from natural sources. 
 Salvia miltiorrhiza, has been of particular interest to our group over the past decade. The 
rhizome of Salvia miltiorrhiza Bunge, also known as Tanshen in traditional Chinese medicine 
(TCM), has been used extensively throughout Chinese history for a variety of ailments. Coronary 
heart diseases such as angina pectoris and myocardial infarction, along with disorders of the 
13 
 
blood vessels such as atherosclerosis and blood clotting abnormalities are just a few of the 
ailments treated with Tanshen.
7,8 
Extensive work has been done to determine the bioactive 
constituents of Tanshen, and more than 70 compounds have been isolated. These compounds 
have been divided into two groups, water-soluble and lipophilic. In 2004, Dr. Xihong Wang 
isolated neo-tanshinlactone (NTL, 11) (Figure 2-1) from an ethanol extract of Salvia 
miltiorrhiza. After evaluating 11 in vitro, it was found that 11 expressed significant anti-breast 
cancer activity in comparison to Tamoxifen. Neo-tanshinlactone exhibited a 10-fold increase in 
potency and was 20-fold more selective than Tamoxifen when tested against ER+ and HER++ 
breast cancer cells.
9 
Further studies done by Dr. Wang led to the development of 4-ethyl neo-
tanshinlactone (ENTL, 12) (Figure 2-1), which displayed increased potency in comparison to 11 
against breast cancer cell lines MCF-7 and SK-BR-3.
10 
Research on 11 and 12 was continued by 
Dr. Yizhou Dong, from our group, who designed numerous analogues of 11 to elucidate  
structure-activity relationship (SAR) correlations for this compound. Dr. Dong focused his 
studies on optimization of the synthesis of 12 and the systematic breakdown of the ring 
structures of 11, as depicted by the wavy lines in Figure 2-2. In general, Dr. Dong found several 
important SAR correlations: 1) the C-4 position was important for anti-breast cancer activity and 
selectivity with ethyl being the most effective along with 2-bromoethyl and propyl; 2) the C-17 
and C-16 positions were also important for activity with a methyl group at C-17 and a hydrogen 
atom at C-16 being the most favorable combination; 3) the lactone ring-C was essential for 
activity; 4) unsaturated rings were preferable over their saturated counterparts for rings A and D, 
an aromatic moiety for ring-A and a furan moiety for ring-D being the most preferable (Figure 2-
2).
11,12
 Due to these findings, we felt that continued modification of 11 was warranted to design 
novel analogues and develop new lead compounds. 
14 
 
 
Figure 2-1. Neo-tanshinlactone and its analogue 4-ethyl neo-tanshinlactone 
 
 
Figure 2-2. Systematic breakdown of NTL used to elucidate SAR 
 
 
 
2.2  Design 
 The goal of the design of analogues 13, 14, and 15, and more generally the scaffolds A, 
B, and C was to utilize bioisosterism to systematically replace specific oxygens of 11 with 
nitrogens (Figure 2-3). In replacing these oxygens with nitrogens, we can observe how changes 
in hydrophobicity and increased numbers of hydrogen bonding atoms affect the cytotoxicity of 
the new compounds against cancer cell lines. Also, the replacement of an oxygen atom with a 
nitrogen atom in the lactone ring and furan ring of scaffolds B and C, respectively, will allow for 
the attachment of substituents to further explore the SAR of neo-tanshinlactone. 
15 
 
 
Figure 2-3. Design of scaffolds A, B, and C along with  
corresponding analogues 13, 14, and 15  
 
 
 
2.3 Chemistry 
2.3.1 Chemistry of 1-ethyl-6-methylfuro[2',3':4,5]pyrano[2,3-e]indol-5(1H)-one (13) 
The synthesis of analogue 13 was achieved in five steps with an overall yield of 16% 
(Scheme 3-1). Sodium hydride was first used, along with the alkyl halide (iodoethane), to 
achieve N-alkylation of 16.
13
 Sodium hydride was again used to generate the enolate form of 16, 
allowing for the coupling with EtOAc to give 17.
14
 Dehydrogenation of 18 using DDQ afforded 
19.
14
 Next, sodium hydride was used, along with an acylating agent (diethyl carbonate), to 
produce 20 via acylation and internal ring cyclization.
15,16
 The last step utilized a tandem 
alkylation/intramolecular Aldol reaction to produce 13.
12 
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Scheme 2-1. Synthetic pathway to analogue 13 
 
 
Reagents and conditions: (a) NaH, EtI, THF 0°C  rt, Ar, overnight; (b) NaH, EtOAc, DME, 
0°C  reflux, Ar, 3 h; (c) DDQ, 1,4-dioxane, relux, 2 h; (d) NaH, diethyl carbonate, toluene, 
100°C, 5 h; (e) chloroacetone, AcOH, ammonium acetate, toluene, EtOH, rt 60°C  reflux, 5 
h. 
 
2.3.2 Chemistry of 5-ethyl-1-methylbenzo[h]furo[3,2-c]quinolin-11(10H)-one (14) 
 The synthesis of analogue 14 was achieved in eight steps with a yield of 2% through the 
first five steps (Scheme 2-2). The overall yield was not determined because only an analytical 
sample of the final product was isolated for NMR and MS analysis. The first three steps have 
been used in the synthesis of previously synthesized neo-tanshinlactone analogues. These steps 
include the use of a Grignard reaction with zinc chloride as a catalyst, and subsequent oxidation 
with the use of Pd/C to produce 22 from 21.
12
 Boron tribromide was then used to demethylate 22 
17 
 
to produce the naphthol 23.
12
 The aryloxyamide 24 was produced by treating the naphthol with 
ethyl 2-bromopropionate to generate the naphthalene ester, followed by production of the amide 
24 via amination of the ethyl ester.
17
 The naphthylamine 25 was generated from the 
aryloxyamide using potassium hydroxide via cleavage of the aryl C-O bond and subsequent 
cleavage of the amide C-N bond.
17
 Friedel-Craft’s acylation of the naphthylamine with boron 
trichloride, aluminum chloride, and acetonitrile generated 26.
18
 From 26, the previous method of 
acylation and internal cyclization gave 27, followed by tandem alkylation/intramolecular Aldol 
reactions were generate 14.
12 
 
Scheme 2-2. Synthetic pathway to analogue 14 
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Reagents and conditions: (a) EtMgBr, ZnCl2, THF, rt  0°C  rt, Ar, overnight; (b) Pd/C 
(10%), Triglyme, 250°C, 2 days; (c) BBr3, DCM, 0°C  reflux, Ar, 3 h; (d) (i) ethyl 2-
bromopropionate, K2CO3, KI, acetone, reflux, 12 h; (ii) NH4OH (28-30%), EtOH, rt, 18 h; (e) 
KOH, DMSO, 140°C, 12 h; (f) BCl3, AlCl3, ACN, DME, 0°C  reflux, Ar, 24 h; (g) NaH, 
diethyl carbonate, toluene, 100°C, Ar, 5 h; (h) chloroacetone,  AcOH, ammonium acetate, EtOH, 
toluene, rt  60°C  reflux, Ar, 24 h. 
 
2.3.3 Chemistry of 6-ethyl-1-methylbenzo[7,8]chromeno[4,3-b]pyrrol-11(3H)-one (15) 
 Progress has been made toward the synthesis of 15 (Scheme 2-3), generating the two 
reagents necessary to perform the final step of the total synthesis. The intermediate, 4-chloro-7-
ethyl-2H-benzo[h]chromen-2-one (29) and reagent (2-methyl-1,3-dioxolan-2-yl)methanamine, 
have been synthesized with an overall yield of 4% and 14%, respectively. For compound 29, 
previously described methods produced the naphthol intermediate 23.
12
 Meldrum’s acid (the 
cyclic form of diethyl malonate) was used to generate the monoester of 23 under solvent-free 
conditions.
19,20
 Eaton’s reagent (7.7% phosphorous pentoxide solution in methanesulfonic acid) 
was then used to promote a Friedel-Crafts acylation, producing 28.
19,20
 Substitution of the 
hydroxyl group for a chlorine atom using phosphorous oxychloride and triethylamine afforded 
compound 29.
21
 (2-methyl-1,3-dioxolan-2-yl)methanamine was synthesized in four steps 
(Scheme 2-4) using 1-amino-2-propanol, 30, as the starting material. The amine was first 
protected using benzyl chloroformate in the presence of 4-DMAP and triethylamine to generate 
31.
22
 Next, the hydroxyl group in 31 was oxidized to the ketone group, in 32, using the Swern 
oxidation
23
, followed by the use of ethylene glycol and pyridinium p-toluenesulfonate (PPTS) to 
produce the acetal group, in 33.
22
 Finally, the amine was deprotected by removing the 
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carboxybenzyl group via hydrogenation using Pd(OH)2/C under H2 atmosphere to afford the 
target compound (2-methyl-1,3-dioxolan-2-yl)methanamine, (34).
22
 The next step, which has yet 
to be completed, would be to react compounds 29 and 34 in the presence of triethylamine, 
followed by an acetic acid/H2O work up to afford the final compound 15.
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Scheme 2-3. Proposed synthetic pathway to analogue 15 
 
 
 
Reagents and conditions: (a) EtMgBr, ZnCl2, THF, rt  0°C  rt, Ar, overnight; (b) Pd/C 
(10%), Triglyme, 250°C, 2 days; (c) BBr3, DCM, 0°C  reflux, Ar, 3 h; (d) (i) Meldrum’s acid, 
90°C, 5 h; (ii) Eaton’s reagent, 70°, 1.5 h; (e) POCl3, triethylamine, relux, 1 h; (f) (2-methyl-1,3-
dioxolan-2-yl)methanamine, triethylamine, EtOH, reflux, 24 h. 
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Scheme 2-4. Synthetic pathway to (2-methyl-1,3-dioxolan-2-yl)methanamine reagent 34 
 
 
 
 
 
 
 
 
 
 
 
 
Reagents and conditions: (a) Benzyl chloroformate, DMAP, triethylamine, DMSO, 50°C, Ar, 5 
h; (b) oxalyl chloride, DMSO, triethylamine, DCM, -78°C  rt, 1.3 h; (c) PPTS, ethylene 
glycol, benzene, reflux, 4 h; (d) Pd(OH)2/C (20%), EtOAc, H2, 50 psi, 5 h. 
 
2.4 Results and Conclusions 
 Analogue 13 was evaluated in vitro against seven different cancer cell lines: SK-BR-3 
(ER/PgR-negative, HER2-overexpressing breast cancer); MCF-7 (ER-postive, PgR±, HER2-
negative breast cancer); ZR-75-1 (ER/PgR/HER2-positive breast cancer); MDA-MB-231 (triple-
negative (ER,PgR, and erbB2(HER2) negative) breast cancer); A549 (lung adenocarcinoma); KB 
(originally isolated as the epidermoid carcinoma of the nasopharynx, but now clarified as HeLa – 
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cervical cancer); and KB-VIN (multidrug-resistant KB cell line). Paclitaxel, a clinically used 
anti-breast cancer agent was used for comparison. Compound 13 (JDB5-54 in Figure 2-1) 
showed no significant cytotoxicity with the average IC50 being greater than 34 µM for the three 
non-breast cancer cell lines and the triple negative breast cancer cell lines (Table 2-1). 
Compound 13 exhibited a decreased potency in comparison to NTL and ENTL, and the 
selectivity towards breast cancer has also diminished. In conclusion, we have successfully 
synthesized two novel neo-tanshinlactone analogues, 13 and 14, and have made progress toward 
the synthesis of a third novel analogue, 15. 
 
Table 2-1. Cytotoxicity assay results for analogue 13 
 
 
 
 
 
SK-BR-3, ER-negative, PgR-negative, HER2-overexpressed breast cancer; MCF-7, ER-
positive, PgR±, HER2-negative breast cancer; ZR-75-1, ER-positive, PgR-negative, HER2-
overexpressed breast cancer; MDA-MB-231, Triple-negative (ER-nega/PgR-nega/erbB2 
(HER2)-nega) breast cancer A549, Lung adenocarcinoma;; KB, originally isolated as the 
epidermoid carcinoma of the nasopharynx (ATCC stock cell line KB is recently clarified as the 
HeLa) KB-VIN, Multidrug-resistant KB cell line. 
 
2.5 Future Studies 
 Continued research will be done on scaffolds A, B, and C. Focus will be on completing 
the synthesis of analogue 15 and linking new moieties to the pyrrole nitrogen and to further 
explore the SAR of neo-tanshinlactone. Analogue 14 will also be explored in more depth; for 
example, new moieties that are known to interact with progesterone receptors will be added to 
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the nitrogen of the lactam ring which replaced one lactone oxygen in neo-tanshinlactone. Further 
studies will also be done to increase hydrophobicity, in hopes to increase membrane 
permeability. 
 
2.6 Experimental Section 
2.6.1 Chemistry 
 Materials and Methods. 
1
H NMR spectra were measured on a Varian 400 MHz 
VNMRS spectrometer using TMS as an internal standard. The solvent used was either CDCl3 or 
(CD3)2SO, as indicated in the detailed procedure. Mass spectra were measured on a Shimadzu 
LCMS-2010 instrument. TLC analysis was performed on Sorbent Technologies aluminum 
backed silica XG TLC plates and preparatory TLC was performed on ANALTECH Uniplate 
Silica Gel GF 1500 micron plates. Flash chromatography was performed on either Teledyne Isco 
CombiFlashRf or Biotage Isolera Prime instruments using Teledyne Isco RediSepRf normal 
phase columns and 230-400 mesh silica gel from Fisher Chemical. Chemicals were obtained 
from Aldrich, Fisher, TCI America, or Acros Organics.  
Synthesis of 1-ethyl-6-methylfuro[2',3':4,5]pyrano[2,3-e]indol-5(1H)-one (13). 
1-Ethyl-1,5,6,7-tetrahydro-4H-indol-4-one, 17. To cooled solution of 1,5,6,7-
tetrahydro-4H-indol-4-one (1.35 g, 10 mmol) in THF (30 mL) at 0 °C was added sodium hydride 
(1.00 g, 25 mmol) under argon atmosphere. The mixture was stirred at 0 °C for 30 min, and then 
iodoethane (1.2 mL, 15 mmol) was added. The remaining mixture was allowed to warm to rt and 
stirred overnight. After the reaction was completed, as determined by TLC analysis, excess 
sodium hydride was quenched with the addition of H2O (30 mL) and the mixture was poured into 
a separatory funnel. Ethyl acetate (EtOAc, 30 mL x 3) was used to extract the organic layer. The 
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organic layer was then dried over magnesium sulfate (MgSO4), filtered, concentrated in vacuo, 
and purified via flash chromatography over silica gel, eluting with EtOAc:hexane (1:4), to give 
17 as a pale yellow viscous oil. 1.46 g (90% yield). 
1
H NMR (400 MHz, CDCl3, ppm): δ 6.59-
6.58 (1H, d, J = 4 Hz, aromatic), 6.56-6.55 (1H, d, J = 4 Hz, aromatic), 3.90-3.84 (2H, q, J = 8 
Hz, CH2), 2.76-2.72 (2H, t, J = 8 Hz, CH2), 2.49-2.45 (2H, t, J = 8 Hz, CH2), 2.19-2.15 (2H, m, 
CH2), 1.41-1.39 (3H, t, J = 4 Hz, CH3) 
 5-Acetyl-1-ethyl-4-oxo-4,5,6,7-tetrahydroindole, 18. To a stirred solution of sodium 
hydride (5.40 g, 135 mmol) in dry 1,2-dimethoxyethane (30 mL) was added 1-ethyl-1,5,6,7-
tetrahydro-4H-indol-4-one (1.47 g, 9 mmol) in 25 mL dry 1,2-dimethoxyethane at 0 °C under 
argon atmosphere. The reaction mixture was stirred for 30 min and EtOAc (4.4 mL, 45 mmol) 
was added dropwise. The reaction mixture was then heated to reflux for 3 h. After completion of 
the reaction as determined by TLC analysis, ice cold NH4Cl was added dropwise to quench the 
reaction and the mixture was then poured into a separatory funnel containing NH4Cl. The 
organic layer was extracted with EtOAc (3 x 50 mL), washed with brine, dried over MgSO4, 
filtered and concentrated under reduced pressure. The crude product was purified by flash 
chromatography over silica gel, eluting with EtOAc:hexane (1:4) to give a light yellow viscous 
oil. 756 mg (41% yield). 
1
H NMR (400 MHz, CDCl3, ppm): δ 6.59-6.58 (1H, d, J = 4 Hz, 
aromatic), 6.54-6.53 (1H, d, J = 4 Hz, aromatic), 3.87-3.81 (2H, q, J = 8 Hz, CH2), 3.52-3.50 
(1H, t, J = 8 Hz, CH), 3.04-2.97 (1H, m, CH2), 2.70-2.63 (1H, m, CH2), 2.58-2.51 (2H, m, CH2), 
2.29 (1H, s, CH3), 2.24-2.19 (1H, m, CH2), 1.38-1.36 (3H, t, J = 4, CH2). MS: m/z (M+2) 207. 
 5-Acetyl-4-hydroxy-1-ethyl-indole, 19. To dry 1,4-dioxane (20 mL) was added 5-acetyl-
1-ethyl-4-oxo-4,5,6,7-tetrahydroindole (756 mg, 3.68 mmol) and 2,3-dichloro-5,6-dicyano-p-
benzoquinone (DDQ, 1.00 g, 4.42 mmol). The mixture was refluxed for 2 h after which the 
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mixture was cooled in an ice bath, filtered through celite, and washed with 1,4-dioxane. The 
filtrate was then evaporated under reduced pressure. The remaining crude product was purified 
via flash chromatography over silica gel, eluting with EtOAc:hexane (1:5) to give a pale yellow 
solid. 481 mg (64%). 
1
H NMR (400 MHz, CDCl3, ppm): δ 13.63 (1H, s, OH), 7.51-7.49 (1H, d, 
J = 8 Hz, aromatic), 7.35-7.25 (1H, d, J = 4 Hz, aromatic), 6.84-6.82 (1H, d, J = 8 Hz, aromatic), 
6.79-6.78 (1H, d, J = 4 Hz, aromatic), 4.18-4.12 (2H, q, J = 8 Hz, CH2), 2.64 (3H, s, CH3), 1.49-
1.45 (3H, t, J = 8 Hz, CH3). 
 7-Ethyl-4-hydroxypyrano[2,3-e]indol-2(7H)-one, 20. To a stirred suspension of sodium 
hydride (60% dispersion in mineral oil, 473 mg, 11.83 mmol) in anhydrous toluene (15 mL) was 
added dropwise 5-acetyl-4-hydroxy-1-ethyl-indole (481 mg, 2.37 mmol) in 10 mL anhydrous 
toluene under argon atmosphere. Diethyl carbonate (0.43 mL, 3.56 mmol) in 5 mL anhydrous 
toluene was added dropwise to the reaction vessel and the mixture was heated to 100 °C for 5 h. 
The solvent was removed under reduced pressure and the remaining residue was treated with 
H2O (25 mL). The solution was acidified to a pH of 1-2 with 1M HCl causing a precipitate to 
form. The precipitate was filtered and washed several times with H2O. The resulting crude 
product was used in the next step without further purification. Pale  yellow solid. 
1
H NMR (400 
MHz, (CD3)2SO, ppm): δ 12.19 (1H, s, OH), 7.56-7.54 (1H, d, J = 8 Hz, aromatic), 7.53-7.52 
(1H, d, J = 4 Hz, aromatic), 7.49-7.47 (1H, d, J = 8 Hz, aromatic), 6.72-6.71 (1H, d, J = 4 Hz, 
aromatic), 5.49 (1H, s, CH), 4.31-4.25 (2H, q, J = 8 Hz, CH2), 1.40-1.36 (3H, t, J = 8 Hz, CH3). 
 1-Ethyl-6-methylfuro[2',3':4,5]pyrano[2,3-e]indol-5(1H)-one (13). To a room 
temperature solution of 1-ethyl-6-methylfuro[2',3':4,5]pyrano[2,3-e]indol-5(1H)-one (100 mg, 
0.44 mmol) in toluene (20 mL) was added a mixture of AcOH (0.13 mL, 2.18 mmol) and 
ammonium acetate (168 mg, 2.18 mmol) in EtOH (5 mL) under argon atmosphere. 
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Chloroacetone (0.174 mL, 2.18 mmol) was then added and the mixture was stirred at rt for 30 
min, heated to 60°C for 30 min, followed by heating to reflux for 5 h. When no further 
transformation occurred as determined by TLC analysis, the reaction mixture was cooled to rt, 
diluted with H2O, and the organic layer was extracted with EtOAc (3 x 30 mL). The organic 
layers were combined, dried over MgSO4, filtered, and the solvent was removed under reduced 
pressure. The remaining crude product was purified via flash chromatography over silica gel, 
eluting with EtOAc:hexane (1:6). 83 mg (71% yield). Pale yellow solid. 
1
H NMR (400 MHz, 
CDCl3, ppm): δ 7.64-7.62 (1H, d, J = 8 Hz, aromatic), 7.34 (1H, s, aromatic), 7.31-7.29 (1H, d, J 
= 8 Hz, aromatic), 7.18-7.17 (1H, d, J = 4 Hz, aromatic), 6.95-6.94 (1H, d, J = 4 Hz, aromatic), 
4.26-4.20 (2H, q, J = 8 Hz, CH2), 2.39 (3H, s, CH3), 1.53-1.49 (3H, t, J = 8 Hz, CH3). MS: m/z 
268. 
 
Synthesis of 5-ethyl-1-naphthol intermediate 23. 
 1-Ethyl-5-methoxynaphthalene, 22. To a solution of ethylmagnesium bromide (1.0 M 
in THF, 85.13 mL, 85.13 mmol) was added zinc (II) chloride (0.5 M in THF, 11.36 mL, 5.68 
mmol) at rt under argon atmosphere. The solution was stirred at rt for 1 h then cooled to 0°C at 
which point 5-methoxy-1-tetralone (10 g, 56.75 mmol) in 80 mL THF was added via syringe. 
The ice bath was removed and the mixture was allowed to warm to rt and stirred overnight. 
NH4Cl was used to quench the reaction mixture and the organic layer was extracted with EtOAc 
(3 x 100 mL). The organic layers were combined, dried over MgSO4, filtered, and concentrated 
under reduced pressure. Flash chromatography over silica gel was used to collect compound 21 
using an EtOAc-hexane gradient. 7.60 g (65% yield). To a solution of 21 (7.59 g, 36.79 mmol) in 
30 mL triglyme was added Pd/C (10% by weight, 7.59 g) and the mixture was refluxed for 2 d. 
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Once cooled, the mixture was filtered through celite, washed with EtOAc (3 x 50 mL), poured 
into a separatory funnel, extracted with EtOAc (3 x 50 mL), dried over MgSO4, and the solvent 
was removed under reduced pressure. Flash chromatography was done over silica gel, eluting 
with EtOAc:hexane (1:9) to afford 1-ethyl-5-methoxynaphthalene. 4.13 g (60% yield). Light 
yellow viscous oil. 
1
H NMR (400 MHz, CDCl3, ppm): δ 8.16-8.14 (1H, d, J = 8 Hz, aromatic), 
7.64-7.62 (1H, d, J = 8 Hz, aromatic), 7.43-7.42 (1H, d, J = 4 Hz, aromatic), 7.41-7.39 (1H, t, J = 
4 Hz, aromatic), 7.38-7.34 (1H, t, J = 8 Hz, aromatic), 6.83-6.82 (1H, d, J = 4 Hz, aromatic), 
4.00 (1H, s, OCH3), 3.12-3.06 (2H, q, J = 8 Hz, CH2), 1.39-1.35 (3H, t, J = 8 Hz, CH3). MS: m/z 
186. 
 5-Ethyl-1-naphthol, 23. To a stirred solution of 1-ethyl-5-methoxynaphthalene (4.12 g, 
22.1 mmol) in 25 mL anhydrous DCM at 0°C was added boron tribromide (1.0 M in DCM, 66 
mL, 66 mmol) dropwise. After removing the ice bath, the reaction mixture was allowed to warm 
to rt and heated to reflux for 3 h. After completion of the reaction as determined by TLC 
analysis, the reaction mixture was cooled to rt. H2O was carefully added dropwise to quench 
remaining boron tribromide, poured into a separatory funnel containing H2O, extracted with 
DCM (2 x 75 mL), dried over MgSO4, filtered, and the solvent was removed under reduced 
pressure to afford the crude product. Flash chromatography was done over silica gel, eluting with 
EtOAc:hexane (1:4). 2.99 g (79% yield). Yellow solid. 
1
H NMR (400 MHz, CDCl3, ppm): δ 
8.07-8.05 (1H, d, J = 8 Hz, aromatic), 7.65-7.63 (1H, d, J = 8 Hz, aromatic), 7.44-7.40 (1H, t, J = 
8 Hz, aromatic), 7.36-7.35 (1H, d, J = 4 Hz, aromatic), 7.35-7.31 (1H, t, J = 8 Hz, aromatic), 
6.82-6.81 (1H, d, J = 4 Hz, aromatic), 5.22 (1H, b, OH), 3.12-3.06 (2H, q, J = 8 Hz, CH2), 1.39-
1.35 (3H, t, J = 8 Hz, CH3). MS: m/z 172.  
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Synthesis of 5-ethyl-1-methylbenzo[h]furo[3,2-c]quinolin-11(10H)-one (14). 
 2-((5-Ethylnaphthalen-1-yl)oxy)propanamide, 24. A mixture of 5-ethyl-1-naphthol 
(1.10 g, 6.39 mmol), ethyl 2-bromopropionate (1.24 mL, 9.58 mmol), anhydrous K2CO3 (1.76 g, 
12.77 mmol), and KI (106 mg, 0.64 mmol) was refluxed in dry acetone (30 mL) for 12 h. The 
mixture was cooled to rt and the solvent was removed under reduced pressure. H2O was added to 
the remaining residue, extracted three times with DCM, dried over MgSO4, filtered, and 
concentrated under reduced pressure. Aqueous NH4OH (28-30% NH4 in H2O, 15 mL) was added 
to the residue and the mixture was dissolved in 15 mL of EtOH. This mixture was stirred at rt for 
18 h, then the solvent was removed under reduced pressure, and the remaining residue was 
purified by flash chromatography over silica gel, eluting with an EtOAc-hexane gradient to 
afford the desired aryloxyamide 24. 500 mg (32% yield). Pale pink solid. 
1
H NMR (400 MHz, 
CDCl3, ppm): δ 8.16-8.14 (1H, d, J = 8 Hz, aromatic), 7.72-7.70 (1H, d, J = 8 Hz, aromatic), 
7.46-7.42 (1H, t, J = 8 Hz, aromatic), 7.41-7.37 (1H, t, J = 8 Hz, aromatic), 7.39-7.37 (1H, d, J = 
8 Hz, aromatic), 6.84-6.82 (1H, d, J = 8 Hz, aromatic), 6.43 (2H, b, NH2), 4.90-4.86 (1H, q, J = 8 
Hz, CH), 3.12-3.08 (2H, q, J = 8 Hz, CH2), 1.73-1.71 (3H, d, J = 8 Hz, CH3), 1.39-1.35 (3H, t, J 
= 8 Hz, CH3). MS:m/z 244. 
 5-Ethylnaphthalen-1-amine, 25.  A mixture of the prepared aryloxyamide 24 (1.27 g, 
5.22 mmol) and KOH (586 mg, 10.44 mmol) in 25 mL dry DMSO was heated to 140°C for 12 h. 
The mixture was cooled to rt, diluted with saturated brine, and extracted with DCM. The 
combined organic layers were washed with saturated brine, dried over MgSO4, filtered, and 
concentrated under reduced pressure. Flash chromatography was done over silica gel, using an 
EtOAc-hexane gradient. 200 mg (22% yield). Pale pink solid. 
1
H NMR (400 MHz, CDCl3, ppm): 
δ 7.71-7.69 (1H, d, J = 8 Hz, aromatic), 7.54-7.52 (1H, d, J = 8 Hz, aromatic), 7.40-7.36 (1H, t, J 
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= 8 Hz, aromatic), 7.36-7.29 (2H, m, aromatic), 6.80-6.78 (1H, d, J = 8 Hz, aromatic), 4.13 (2H, 
b, CH2), 3.12-3.08 (2H, q, J = 8 Hz, CH2), 1.39-1.35 (3H, t, J = 8 Hz, CH3). 
 1-(1-Amino-5-ethylnaphthalen-2-yl)ethanone, 26.  To a solution of boron trichloride 
(1.0M solution in DCM, 1.3 mL, 1.3 mmol) was added a solution of 5-ethylnaphthalen-1-amine 
(200 mg, 1.18 mmol) in 10 mL of 1,2-dichloroethane at 0°C under inert atmosphere. Anhydrous 
aluminum chloride (173 mg, 1.3 mmol) and anhydrous acetonitrile (0.062 mL, 1.18 mmol) were 
then added and the mixture was refluxed for 24 h. The solution was then cooled to 0°C, 2N HCl 
was added, and the mixture was stirred at 80°C for 30 min. Then, the mixture was extracted with 
DCM, washed with 1N NaOH and brine, dried over MgSO4, filtered and concentrated under 
reduced pressure to afford the crude product. Flash chromatography was done over silica gel, 
eluting with EtOAc:hexane (1:6). 210 mg (84% yield). Pale yellow solid. 
1
H NMR (400 MHz, 
CDCl3, ppm): δ 7.81-7.79 (1H, d, J = 8 Hz, aromatic), 7.75-7.72 (1H, d, J = 12 Hz, aromatic), 
7.58 (2H, b, NH2), 7.44-7.38 (2H, m, aromatic), 7.27-7.26 (1H, d, J = 4 Hz, aromatic), 3.08-3.02 
(2H, q, J = 8 Hz, CH2), 2.67 (3H, s, CH3), 1.38-1.34 (3H, t, J = 8 Hz, CH3). 
 5-Ethyl-1-methylbenzo[h]furo[3,2-c]quinolin-11(10H)-one, 27. To a stirred suspension 
of sodium hydride (60% dispersion in mineral oil, 197 mg, 4.92 mmol) in anhydrous toluene (5 
mL) was added dropwise 1-(1-amino-5-ethylnaphthalen-2-yl)ethanone (210 mg , 0.98 mmol) in 
3 mL anhydrous toluene under argon atmostphere. Diethyl carbonate (0.18 mL, 1.48 mmol) in 2 
mL anhydrous toluene was added dropwise to the reaction vessel and the mixture was heated to 
100 °C for 5 h. The solvent was removed under reduced pressure and the remaining residue was 
treated with H2O (25 mL). The solution was acidified to a pH of 1-2 with 1M HCl, causing a 
precipitate to form. The precipitate was filtered and washed several times with H2O. To a room 
temperature solution of the crude hydroxylactam intermediate (80 mg, 0.34 mmol) in toulene (10 
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mL) was added a mixture of AcOH (0.096 mL, 1.68 mmol) and ammonium acetate (129 mg, 
1.68 mmol) in EtOH (2 mL) under argon atmosphere. Chloroacetone (0.134 mL, 1.68 mmol) 
was then added and the mixture was stirred at rt for 30 min, heated to 60°C for 30 min, followed 
by heating to reflux for 24 h. When no further transformation occurred as determined by TLC 
analysis, the reaction mixture was cooled to rt, diluted with H2O, and the organic layer was 
extracted with EtOAc (3 x 30 mL). The remaining brown residue was rinsed with EtOAc leaving 
a light yellow solid, which was dissolved in a mixture of CHCl3 and MeOH and subjected to 
preparatory TLC analysis using a EtOAc:hexane (1:1) solvent mixture to separate the final 
product from the starting material. The band corresponding to the final product was scraped from 
the TLC plate and subjected to flash chromatography without a column, eluting with 
CHCl3:MeOH (4:1) to provide a sample for NMR analysis. Pale yellow solid. 
1
H NMR (400 
MHz, CDCl3, ppm): δ10.06 (1H, s, NH), 8.21-8.19 (1H, d, J = 8 Hz, aromatic), 7.94-7.92 (1H, d, 
J = 8 Hz, aromatic), 7.63-7.59 (1H, t, J = 8 Hz, aromatic), 7.51-7.49 (1H, d, J = 8 Hz, aromatic), 
7.46 (1H, s, aromatic), 3.19-3.13 (2H, q, J = 8 Hz, CH2), 2.51 (3H, s, CH3), 1.43-1.39 (3H, t, J = 
8 Hz, CH3). MS: m/z (M+1) 278. 
Synthesis of (2-methyl-1,3-dioxolan-2-yl)methanamine (34). 
 Benzyl 2-oxopropylcarbamate, 32. Benzyl chloroformate (25.70 mL, 180 mmol) was 
added dropwise under argon atmosphere to a mixture of 1-amino-propanol (3.12 mL, 40 mmol), 
4-(dimethylamino)pyridine (978 mg, 8 mmol), and triethylamine (24 mL, 172 mmol) in dry 
DMSO (50 mL). The mixture was stirred for 5 h at 50°C, cooled to rt, quenched with aqueous 
saturated sodium bicarbonate, and extracted with EtOAc (3 x 50 mL). The combined organic 
layers were dried over MgSO4, filtered and concentrated under reduced pressure. Flash 
chromatography was done over silica gel, eluting with EtOAc:hexane (1:5). The combined 
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fractions were concentrated under reduced pressure to afford the intermediate benzyl 2-
hydroxypropylcarbamate, 31. DMSO (3.57 mL50.21 mmol) was added to a solution of oxalyl 
chloride (3.28 mL, 37.65 mmol) in 40 mL DCM at -78°C under argon atmosphere. This mixture 
was stirred for 20 min after which a solution of benzyl 2-hydroxypropylcarbamate in 20 mL was 
added and the mixture was stirred for a further 1 h. Triethylamine (10.66 mL) was then added to 
the reaction and the mixture was allowed to warm to rt, followed by a wash with 1M HCl and 
aqueous saturated sodium bicarbonate, successively. The organic layer was dried over MgSO4, 
filtered, and concentrated under reduced pressure. Flash chromatography was done over silica 
gel, eluting with EtOAc:hexane (1:2). 1.40 g (17% yield). Clear oil. 
1
H NMR (400 MHz, CDCl3, 
ppm): δ 7.36-7.31 (5H, m, aromatic), 5.46 (1H, b, NH), 5.12 (2H, s, CH2), 4.1 (2H, s, CH2), 2.19 
(3H, s, CH3). MS: m/z (M+1) 208. 
 Benzyl (2-methyl-1,3-dioxolan-2-yl)methylcarbamate, 33. A mixture of benzyl 2-
oxopropylcarbamate (1.40 g, 6.75 mmol), pyridinium p-toluenesulfonate (71 mg, 0.28 mmol), 
and ethylene glycol (1.21 mL, 21.61 mmol) in dry benzene (20 mL) was refluxed for 4 h. H2O 
was added to quench the reaction and the organic layer was washed with H2O, saturated aqueous 
sodium bicarbonate, and brine. The organic phase was dried over MgSO4, filtered, and 
concentrated under reduced pressure. Flash chromatography was done over silica gel, eluting 
with EtOAc:hexane (1:3). 1.62 g (95% yield). Clear oil. 
1
H NMR (400 MHz, CDCl3, ppm): δ 
7.36-7.31 (5H, m, aromatic), 5.11 (2H, s, CH2), 4.97 (1H, b, NH), 3.99-3.88 (4H, m, (CH2)2), 
3.36-3.35 (2H, d, J = 8Hz, CH2), 1.33 (3H, s, CH3). MS: m/z (M+1) 252. 
(2-Methyl-1,3-dioxolan-2-yl)methanamine, 34.  Benzyl (2-methyl-1,3-dioxolan-2-
yl)methylcarbamate (1.62 g, 6.44 mmol), Pd(OH)2/C (20% loading on activated charcoal, 1.69 
g), and EtOAc (40 mL) were added to a Parr shaker hydrogenation apparatus and shaken under 
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H2 atmosphere at 50 psi. The mixture was filtered through celite and the filtrate was evaporated 
under reduced pressure and dried in the air overnight to afford (2-methyl-1,3-dioxolan-2-
yl)methanamine. 655 mg (87% yield). Pale yellow solid. 
1
H NMR (400 MHz, CDCl3, ppm): δ 
4.01-3.97 (4H, m, (CH2)2), 2.76 (2H, s, CH2), 1.48 (2H, s, NH2), 1.30 (3H, s, CH3). MS: m/z 117. 
 
Synthesis of 6-ethyl-1-methylbenzo[7,8]chromeno[4,3-b]pyrrol-11(3H)-one (15). 
 7-Ethyl-4-hydroxy-2H-benzo[h]chromen-2-one, 28. A mixture of 5-ethyl-1-naphthol 
(1.34 g, 7.75 mmol) and Meldrum’s acid (1.17 g, 8.14 mmol) was heated to 90°C for 5 h. After 
cooling to rt, the mixture was then diluted with saturated aqueous sodium bicarbonate and 
extracted with EtOAc. The aqueous layer was acidified to a pH of 1-2 using 12M HCl and 
extracted several times with DCM. The organic layers were combined, dried over MgSO4, 
filtered, and concentrated under reduced pressure to afford the malonic acid ester intermediate. 
Eaton’s reagent (13 mL) was then added and the mixture was heated to 70°C for 1.5 h. After the 
reaction mixture cooled to rt, H2O was added while stirring, the precipitate was filtered off and 
washed several times with H2O, dried in the air overnight and recrystallized from EtOH. 610 mg 
(33% yield). Light yellow solid. 
1
H NMR (400 MHz, (CD3)2SO, ppm): δ 12.61 (1H, s, OH), 
8.26-8.24 (1H, d, J = 8 Hz, aromatic), 8.01-7.98 (1H, d, J = 12 Hz, aromatic), 7.88-7.84 (1H, t, J 
= 8 Hz, aromatic), 7.66-7.58 (2H, m, aromatic), 5.69 (1H, s, CH), 3.15-3.09 (2H, q, J = 8 Hz, 
CH2), 1.34-1.30 (3H, t, J = 8 Hz, CH3). MS: m/z 240.  
 4-Chloro-7-ethyl-2H-benzo[h]chromen-2-one, 29. A mixture of 7-ethyl-4-hydroxy-2H-
benzo[h]chromen-2-one (360 mg, 1.5 mmol), triethylamine (0.21 mL, 1.5 mmol), and 5 mL 
phosphorous oxychloride was heated to reflux for 1 h. The mixture was cooled to rt, poured into 
ice water and extracted with DCM. The organic layer was dried over MgSO4, filtered and 
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concentrated under reduced pressure. Flash chromatography was done over silica gel, eluting 
with EtOAc:hexane (1:9).  160 mg (41% yield). Light yellow solid. 
1
H NMR (400 MHz, CDCl3, 
ppm): δ 8.47-8.45 (1H, d, J = 8 Hz, aromatic), 7.99-7.97 (1H, d, J = 12 Hz, aromatic), 7.88-7.86 
(1H, d, J = 8 Hz, aromatic), 7.62-7.54 (2H, m, aromatic), 6.69 (1H, s, CH), 3.17-3.11 (2H, q, J = 
8 Hz, CH2), 1.41-1.37 (3H, t, J = 8 Hz, CH3). MS: m/z 259.  
 
2.6.2 Cytotoxicity Assay 
 The following human tumor cell lines were used in the assay: A549 (lung carcinoma), 
KB (originally isolated from epidermoid carcinoma of the nasopharynx), KB-VIN (VIN-resistant 
KB subline showing MDR phenotype by overexpressing P-gp), MCF-7 (estrogen receptor (ER)-
positive, HER2-negative breast cancer), SK-BR-3 (ER-negative, progesterone receptor (PgR)-
negative, HER2-overexpressing breast cancer), ZR-75-1 (ER-positive, HER2-overexpressing 
breast cancer) . All cell lines were obtained either from the Lineberger Comprehensive Cancer 
Center (UNC-CH) or from the ATCC (Manassas, VA), except KB-VIN, which was a generous 
gift of Professor Y.-C. Cheng (Yale University). All cell lines were maintained in RPMI-1640 
medium containing 2 mM l-glutamine and 25 mM HEPES (HyClone), supplemented with 10% 
heat-inactivated fetal bovine serum (HyClone), 100 µg/mL streptomycin, 100 IU/mL penicillin, 
and 0.25 µg/mL amphotericin B (Cellgro) at 37 C with 5% CO2 in air. KB-VIN cell line was 
maintained in the presence of 100 nM VIN. Freshly prepared cell suspensions were seeded with 
compounds in 96-well microtiter plates at densities of 4,000-7,500 cells per well for A549, 
MDA-MB-231, KB and KB-VIN. 10,000-12,500 cells per well were used for MCF-7, SK-BR-3 
and ZR-75-1. Under the assay conditions, the highest concentration of DMSO in the cultures 
(0.1% v/v) was without effect on cell growth. The living cells were fixed in 10% trichloroacetic 
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acid after 72 h,  and then stained with 0.04% sulforhodamine B (SRB). Then, the protein-bound 
SRB was solubilized with 10 mM Tris base, and absorbance of SRB was measured at 515 nm 
using a microplate reader (ELx800, BioTek) operated by Gen5 software (BioTek). The mean 
IC50 is the concentration of agent that reduced cell growth by 50% compared with vehicle 
(DMSO) control under the experimental conditions and is the average from at least three 
independent experiments with duplicate samples. 
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